Patients had a disease-activity score based on 28 joint count (DAS28) >3.2, with an active disease defined as at least 2 of the following criteria: ≥ 6 painful joints, ≥ 3 swollen joints, erythrocyte sedimentation rate (ESR) ≥ 20 mm/h or a C-reactive protein (CRP) ≥ 10mg/L.
Detailed Inclusion and Exclusion criteria
Patients had a disease-activity score based on 28 joint count (DAS28) >3.2, with an active disease defined as at least 2 of the following criteria: ≥ 6 painful joints, ≥ 3 swollen joints, erythrocyte sedimentation rate (ESR) ≥ 20 mm/h or a C-reactive protein (CRP) ≥ 10mg/L.
Menstruating women could only enter the study in the early follicular phase of their menstrual cycle. The concomitant use of stable doses of disease-modifying anti-rheumatic drugs (DMARDs) for at least 8 weeks, stable prednisolone ≤7•5 mg daily for at least 4 weeks, and stable non-steroidal anti-inflammatory drugs (NSAIDs) for at least 2 weeks was allowed if these doses were continued throughout the study. Key exclusion criteria were as follows: pregnancy or breastfeeding females; corticosteroid injections within the trial or 4 weeks prior to screening; biological agents were not permitted during the trial or within 4 weeks prior to inclusion in the trial (with the exception of infliximab or adalimumab which were not permitted within 3 months prior to inclusion in the trial; and rituximab which was not permitted within 6 months prior to inclusion in the trial). A history of hormone-dependent cancers ever or non-hormone-dependent cancers within 5 years prior to screening; infections requiring intravenous antibiotic treatment within 30 days, or oral antibiotics within 14 days prior to enrolment; significant renal or hepatic impairment; and any treatment with hormone replacement therapy or oral contraception were also exclusion criteria.
During the first three months, patients with disease duration >36 months or patients taking concomitant NSAIDs and prednisiolone were also excluded. Due to slow recruitment, these stricter criteria were removed after the first 6 patients were enrolled. This change was not expected to bias our results, and allowed data generated by this trial to be generalised to a wider RA population.
TNF-α Assay
TNF-α was measured using a high sensitivity bead-based fluorescence immunoassay (Luminex Inc., Austin, Texas, USA) with multiplex technology according to the manufacturers' instructions. No significant variation was noted between duplicates for any sample. Identical lots of critical reagent, of negligible cross reactivity <2%, was supplied by Biorad, Hercules, California, USA. Samples were assayed together within the same microplate on the same day. The assay sensitivity for TNF-α was 0•5 pg/mL. Due to its skewed distribution, the statistical analysis gives both the log and relative change (%) of TNF-α from baseline.
Hormone Assays
Non-competetive immunofluorometric assays were used for the quantitative determination of 
Further Statistical Analyses
The sample size calculation was based on a two-sided significance level of 5% and a power of 80%. Assuming a 10% dropout rate, the trial needed to enrol 49 patients per treatment group to detect a between-group difference of 0•6 DAS28 units with a standard deviation (SD) of
Dichotomous endpoints were compared with the Pearson chi-squared test or the SuissaShuster exact unconditional test, depending on the distribution of expected values (1). The Newcombe hybrid score interval was used to estimate 95% confidence intervals (CI) for the difference between proportions (2). No adjustments for multiple analyses were made, owing to the highly correlated variables. All clinical, biochemical, and safety data were analysed by an intention-to-treat analysis. Only predefined endpoints are presented. The intention-to-treat population was predefined in the protocol as all randomised patients who received any injections of study drug. Missing values were <1% and could, as predefined, be imputed with the last observation carried forward. The assumptions of normality needed for analyses were approximately valid. The Spearman rank correlation coefficient (Spearman's rho) was used to estimate the association between pairs of continuous variables.
Supplementary Results
Cetrorelix onset and offset effect LH and FSH remained stable in the placebo group ( Figure 1C in main article shows change from baseline in LH). Although LH and FSH were reduced as early as day 2 in patients allocated to cetrorelix, there were no significant changes in clinical endpoints compared with patients allocated to placebo until maximal suppression of LH and FSH by day 5. As expected by day 10, LH and FSH increased towards baseline levels after cessation of cetrorelix, with further increases towards baseline by day 15. The same trend was observed with DAS28CRP and with secondary endpoints. No variables in the cetrorelix group exceeded baseline levels after drug cessation. This rapid offset effect was expected owing to the short half-life of cetrorelix.
Core set measures
Each core set measure of disease activity showed non-significant greater improvements in the cetrorelix group compared with the placebo group except for the physician global assessment which was equally reduced in both groups. 
Participant flow 13a
For each group, the numbers of participants who were randomly assigned received intended treatment, and were analysed for the primary outcome Supplement: Figure S1 13b For each group, losses and exclusions after randomization, together with reasons Supplement: Figure S1 Recruitment 
